“Treatment-resistant” means the usual first steps weren’t enough. It does not mean nothing can help. There are many next steps.
One careful review, several ways forward
Start here
A careful review.
Before choosing a treatment, we look closely at the diagnosis, your full treatment history, and anything else making recovery harder, like sleep, pain or alcohol.
Option 1 of 5
Optimize medicines.
Medicines aren’t finished just because some didn’t work. We may adjust doses, switch medicines, add an augmenting medicine, or simplify, following a clear plan rather than trial and error.
Options include dose optimization, switching class, and augmentation (for example an atypical antipsychotic, lithium, or a second antidepressant), plus deprescribing drugs that cause sedation or blunting. In VAST-D, augmenting with aripiprazole produced modestly higher remission than switching to bupropion. Progress is tracked with rating scales such as the PHQ-9.
Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression. IV or IM ketamine may be considered, especially if Spravato hasn’t helped enough.
Both act mainly through the glutamate system (NMDA receptor blockade) and can work faster than conventional antidepressants. Esketamine is FDA-approved for TRD, given in certified clinics under the REMS program. In ESCAPE-TRD, esketamine led to more remissions than quetiapine augmentation at 8 weeks. IV or IM ketamine for depression is off-label and requires informed consent and monitoring.
Transcranial magnetic stimulation uses gentle magnetic pulses on the scalp. You’re awake, there’s no medicine involved, and you can drive yourself home.
FDA-cleared for major depression after insufficient benefit from antidepressants. Standard courses are daily sessions for about 6 weeks; intermittent theta burst delivers a session in about 3 minutes and was noninferior to standard 10 Hz rTMS in THREE-D. Accelerated protocols compress treatment into fewer days. Main side effects are scalp discomfort and headache; seizure is rare.
ECT is one of the most effective treatments for severe depression. We don’t provide it here, but we discuss it honestly and refer you to a trusted program when it’s the right step.
The science
Well establishedFDA labeling / guidelines
Modern ECT is done under general anesthesia with muscle relaxation. It is considered when depression is severe, psychotic, catatonic, life-threatening, involves refusal to eat or drink, or has not responded to multiple treatments. It has among the highest response rates of any depression treatment; memory side effects are its main drawback and are mostly short-term. In nonpsychotic TRD, ELEKT-D found IV ketamine noninferior to ECT.
VNS is FDA-approved as adjunctive long-term treatment for chronic or recurrent depression after four or more failed treatments; benefit builds over months to years. Investigational approaches include psilocybin (in late-stage trials, not FDA-approved) and other neuromodulation methods. Ketamine-assisted psychotherapy is a separate model the clinic is developing.
Treatments are often combined, such as medicines with TMS or esketamine.
Even partial benefit from past treatments is useful information.
Bring to your evaluation
Every psychiatric medicine you remember, with dose and how long
What helped, what caused side effects, and why it stopped
Past TMS, ketamine, ECT or therapy
How the order is decided, with references
Defining treatment-resistant depression
Well established
Treatment-resistant depression (TRD) is usually defined as major depression that has not responded enough to at least two adequate antidepressant trials (adequate dose, adequate duration, taken consistently). In the STAR*D trial, each additional medication step helped fewer people reach remission, which is why there are options beyond medication changes.
Re-evaluate before escalating
Well established
“Resistance” is sometimes pseudo-resistance: an unrecognized bipolar illness, trauma, grief, sleep disorders, chronic pain, substance use, medical illness or medication effects. Each prior trial is reconstructed: drug, dose, duration, adherence, benefit, side effects and why it stopped. Function and safety shape how fast and how intensively to treat.
How sequencing is decided
Severity and safety first: psychosis, catatonia, inability to eat or drink, or high suicide risk push toward faster or higher-intensity care, including ECT referral or a higher level of care.
History: number and adequacy of prior trials, partial responses, tolerability, and comorbidities.
Medical factors: blood pressure and cardiovascular disease (esketamine, ketamine), seizure risk (TMS), pregnancy, substance use.
Practical factors: schedule, transportation, insurance coverage and patient preference.
Every plan is individual, and the order of options varies. For education only; this is not medical advice. Talk with your care team about what fits you.
The takeaway
Treatment-resistant depression is not untreatable.
The next step starts with a careful review of the diagnosis and what has been tried.
Options include adjusting medicines, esketamine or ketamine, TMS, and ECT when it fits.
What you can do next
List the treatments you have tried, with doses and how long you took them.
Compare TMS, Spravato and ketamine in our side-by-side guide.